ALK and non-small cell lung carcinoma: Lorlatinib acts against all known ALK resistance mutations.[11,12] Several clinical trials have shown that lorlatinib is effective in ALK-positive NSCLC patients with secondary ALK resistance mutations.[8,13] As seen in the present case, lorlatinib is effective for tumors that are resistant to second-generation ALK inhibitors, such as alectinib and brigatinib.